FDA Proposes Withdrawing Tavneos: Should Patients Stop Taking It?

The short answer is no: patients should not stop Tavneos on their own just because the FDA has proposed withdrawing it.

On April 27, 2026, the FDA’s Center for Drug Evaluation and Research said it is proposing that Tavneos be withdrawn from the market. But the agency also said Tavneos remains on the market during the process unless the company removes it or the FDA Commissioner later orders it removed. That means this is not the same as an immediate recall.

For people currently taking Tavneos, the most practical next step is to contact the specialist who manages their vasculitis and ask what to do next. That may be a rheumatologist, nephrologist, pulmonologist, or another clinician involved in care.

What changed on April 27, 2026?

The FDA said it is proposing to withdraw approval of Tavneos, the brand name for avacopan. Tavneos was approved in 2021 as an add-on treatment, used with glucocorticoids and other standard therapy, for adults with severe active ANCA-associated vasculitis.

ANCA-associated vasculitis is a rare autoimmune disease in which inflammation damages small- to medium-sized blood vessels. It can affect organs such as the kidneys, lungs, sinuses, nerves, and skin. Because it can become serious, medication changes should usually be made by a clinician who knows the patient’s disease severity, organ involvement, and treatment history.

FDA says it is acting now for two reasons: new information indicates Tavneos has not been shown to be effective for its approved use, and the application that led to approval contained untrue statements of material fact. The agency also said it can no longer conclude there has been a valid demonstration that Tavneos is effective for its approved use.

Why liver safety is also part of the story

The proposed withdrawal came less than a month after a separate FDA drug safety communication, issued on March 31, 2026, about serious liver injury in patients taking Tavneos.

In that safety communication, FDA said it had identified serious postmarketing cases of drug-induced liver injury, including fatal cases. Some cases involved vanishing bile duct syndrome, a rare and potentially severe condition that can lead to permanent liver damage.

FDA told patients taking Tavneos to contact a health care professional immediately if they develop symptoms that may suggest liver injury. Those symptoms include unusual tiredness, nausea, vomiting, unusual itching, light-colored stools, yellowing of the skin or eyes, dark urine, swelling in the stomach or abdomen, or pain in the right upper abdomen.

These symptoms do not automatically mean a person has liver failure or permanent liver damage. But for someone taking Tavneos, they are important warning signs that need prompt medical attention.

What this does not mean

This FDA action does not mean every person who has taken Tavneos has been harmed. It also does not mean every patient should immediately stop treatment.

That distinction matters because ANCA-associated vasculitis can damage major organs, and stopping treatment without a plan could create its own risks. FDA specifically recommends that health care professionals discuss Tavneos and other available treatments with patients while the agency’s final decision is still pending.

It is also important to remember what Tavneos is and is not. It was approved as part of a broader treatment approach, not as a stand-alone cure. FDA’s original approval said it is used with glucocorticoids and other standard-of-care medicines, and it does not eliminate glucocorticoid use.

What patients and caregivers can do now

If you or a family member takes Tavneos, consider these reasonable next steps:

Contact the prescribing specialist and ask whether the current treatment plan should continue while FDA’s process plays out.
Ask whether liver blood-test monitoring is up to date and whether additional monitoring is needed.
Review the FDA warning symptoms so you know what should prompt an urgent call.
Do not stop, skip, or replace Tavneos or other vasculitis medicines unless your care team gives you a safe plan.
Tell your clinician about all prescription drugs, over-the-counter medicines, and supplements you take, because liver risk and treatment decisions may be affected by more than one product.
Follow future FDA updates, since the final regulatory outcome is not yet known.

If someone taking Tavneos develops yellowing of the skin or eyes, dark urine, severe vomiting, severe abdominal pain, worsening swelling of the abdomen, or seems seriously ill, they should seek urgent medical help right away.

Why treatment changes should be individualized

The American College of Rheumatology’s vasculitis guidance reinforces that ANCA-associated vasculitis treatment is not one-size-fits-all. The right plan depends on factors such as which organs are involved, how active the disease is, what treatments the patient has already tried, and what side effects or risks they may face.

That is why a broad public headline about a drug withdrawal proposal should not automatically become an individual medication decision. A person with kidney involvement, lung disease, or recent severe vasculitis may face a different risk-benefit calculation than someone with more stable disease.

MedlinePlus also notes that avacopan is taken by mouth and used along with other medications for these conditions. But patient-specific questions about continuing, stopping, or switching treatment should go back to the clinician managing the case.

What remains uncertain

As of April 29, 2026, Tavneos has not been immediately pulled from the market. FDA has proposed withdrawal, but the process is still ongoing, and the final outcome is not yet known.

For patients and families, the clearest takeaway is practical rather than dramatic: do not panic, do not make sudden medication changes on your own, and do contact the prescribing specialist. The most important questions right now are whether treatment should continue for now, how liver monitoring should be handled, what symptoms require urgent attention, and what alternative treatments may be appropriate if a change becomes necessary.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.